However, the potential of GLP‐1 RAs to regress fibrosis, as well as to prevent the progression of steatosis to NASH and cirrhosis, is still needed to be confirmed by prospective RCTs with more sensitive end‐points of hepatic fibrosis. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.